Literature DB >> 12586030

[Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in spanish hospitals (GEIH-BLEE Project 2002)].

José Ramón Hernández1, Alvaro Pascual, Rafael Cantón, Luis Martínez-Martínez.   

Abstract

INTRODUCTION: To describe demographic aspects of a prospective multicentric nationwide study on Escherichia coli and Klebsiella pneumoniae producing extended spectrum b -lactamases (ESBL) in Spain, between March and June 2000.
METHODS: 352 E. coli and K. pneumoniae strains showing a phenotype compatible to ESBL production were collected from 40 Spanish Hospitals. A form with demographic and clinical data was filled for every isolate. Identification and susceptibility testing (microdilution, NCCLS guidelines) were performed in a reference centre. RESULTS. 240 strains (170 E. coli and 70 K. pneumoniae) produced ESBL. E. coli ESBL (+) strains were isolated in 33 out of 40 participating hospitals, whereas K. pneumoniae were isolated in 17 hospitals. E. coli ESBL (+) prevalence ranged from 0% to 2.4% and K. pneumoniae ESBL (+) from 0% to 16.7%. Fifty-one percent of E. coli ESBL (+) were from outpatients, whereas 93% of K. pneumoniae ESBL (+) were from inpatients. E. coli ESBL (+) were mainly collected from Medicine and Surgery wards and K. pneumoniae from ICU and Paediatrics. ESBL (+) strains were isolated more frequently from urine samples. Patients' ages ranged from 0 to 93 years for E. coli (median 58 years) and 0 to 83 years for K. pneumoniae (median: 1 year). Paediatric cases excluded, these median values were 64 and 53 years, respectively.
CONCLUSIONS: E. coli and K. pneumoniae ESBL (+) were identificated in 90% of the participating hospitals. Although E. coli was more frequently isolated than K. pneumoniae, production of ESBL was more prevalent in K. pneumoniae. Fifty-one percent of ESBL producing E. coli were isolated from outpatients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586030

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  10 in total

1.  Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.

Authors:  Jesús Rodríguez-Baño; Maria Dolores Navarro; Luisa Romero; Luis Martínez-Martínez; Miguel A Muniain; Evelio J Perea; Ramón Pérez-Cano; Alvaro Pascual
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

2.  Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases in Spain: microbiological and clinical features.

Authors:  C Ruiz de Alegría; J Rodríguez-Baño; M E Cano; J R Hernández-Bello; J Calvo; E Román; M A Díaz; A Pascual; L Martínez-Martínez
Journal:  J Clin Microbiol       Date:  2010-12-29       Impact factor: 5.948

3.  In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.

Authors:  M de Cueto; L López; J R Hernández; C Morillo; A Pascual
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum beta-lactamases in Spain.

Authors:  J R Hernández; L Martínez-Martínez; R Cantón; T M Coque; A Pascual
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

5.  Prevalence of Aminoglycoside-Modifying Enzymes in Escherichia coli and Klebsiella pneumoniae Producing Extended Spectrum β-Lactamases Collected in Two Multicenter Studies in Spain.

Authors:  Marta Fernández-Martínez; Belén Ruiz Del Castillo; Maria Jesús Lecea-Cuello; Jesús Rodríguez-Baño; Álvaro Pascual; Luis Martínez-Martínez
Journal:  Microb Drug Resist       Date:  2017-10-03       Impact factor: 3.431

6.  Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-beta-lactamase-producing Escherichia coli isolates.

Authors:  Antonio Sorlozano; Jose Gutierrez; Antonio Jimenez; Juan de Dios Luna; José Luis Martínez
Journal:  J Clin Microbiol       Date:  2007-06-13       Impact factor: 5.948

7.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14

8.  Community transmission of extended-spectrum beta-lactamase.

Authors:  Beatriz Mirelis; Ferran Navarro; Elisenda Miró; Raul Jesús Mesa; Pere Coll; Guillem Prats
Journal:  Emerg Infect Dis       Date:  2003-08       Impact factor: 6.883

9.  Community-onset extended-spectrum β-lactamase producing Escherichia coli in urinary tract infections in children from 2015 to 2016: Prevalence, risk factors, and resistances.

Authors:  Iñigo Pérez Heras; Juan Carlos Sanchez-Gomez; Pedro Beneyto-Martin; Laura Ruano-de-Pablo; Begoña Losada-Pinedo
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

10.  Frequency of microorganisms isolated in patients with bacteremia in intensive care units in Colombia and their resistance profiles.

Authors:  Jorge Alberto Cortes; Aura Lucía Leal; Anita María Montañez; Giancarlo Buitrago; Juan Sebastián Castillo; Lucy Guzman
Journal:  Braz J Infect Dis       Date:  2013-05-14       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.